EGFR and non-small cell lung carcinoma: BI-4020, an inhibitor of EGFR, serves as another intriguing example of a successful macrocyclization application, which has been designed to target tertiary EGFR resistance mutations, such as EGFR-L858R, EGFR-T790M, and EGFR-C797S that occur in NSCLC [2].